ValiRx PLC, a life science company focused on early-stage cancer therapeutics and women's health, has taken the lease on laboratory and office facilities at MediCity Nottingham as it embarks on the next stage of its strategy to launch a translational Contract Research Organization (tCRO).
StockMarketWire.com - Cancer therapy developer ValiRx said it had signed a non-binding letter of intent with TheoremRx to enter into a licence agreement for a cancer treatment.nThe letter encompassed pre-agreed terms to sub-license ValiRx's legacy asset VAL201 for development in the treatment of cancer.
ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, has entered an Evaluation Agreement with a leading London university to investigate a novel technology designed to treat breast cancer.
London, UK - ValiRx plc (AIM:VAL), a clinical stage drug development company, announces today that it has entered into a new agreement with Physiomics plc (“Physiomics”)(AIM:PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The new agreement supersedes the agreement between Physiomics and the Group which was announced on 13 September 2011.
UK-based oncology consultancy company Physiomics has signed a new agreement with clinical stage drug development company ValiRx.